Recent commercial success belies conventional wisdom that vaccines are a low-margin, moribund sector. But will the trend continue? Cormac Sheridan investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Patel, H. & Makarova, A. Emerging Vaccines (Decision Resources Waltham, Massachusetts, December 2008).
Giuliani, M.M. et al. Proc. Nat. Acad. Sci. USA 103, 10834–10839 (2006).
Pass, R.F. et al. NEJM 360, 1191–1199 (2009).
Reap, E.A. et al. Vaccine 25, 7441–7449 (2007).
Wloch, M.K. et al. J. Infect. Dis. 15, 1634–1642 (2008).
Kuklin, N.A. et al. Infect. Immun. 74, 2215–2223 (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. Vaccine market boosters. Nat Biotechnol 27, 499–501 (2009). https://doi.org/10.1038/nbt0609-499
Issue Date:
DOI: https://doi.org/10.1038/nbt0609-499
This article is cited by
-
Recombinant immunotherapeutics: current state and perspectives regarding the feasibility and market
Applied Microbiology and Biotechnology (2010)
